Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/66—Arsenic compounds
  • C07F9/70—Organo-arsenic compounds
  • C07F9/80—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/10—Anthelmintics

Definitions

• novel melaminylthioar senites which are trypanocidal and macrofilaricidal agents can be prepared. They can be provided as the principal active agent in therapeutically useful compositions in association with pharmaceutically acceptable excipients.
• the compounds of this invention may be represented by the formula:
• Y is selected from the group concisting of and n and m are both integers from 2 to
• the invention also includes pharmaceutically acceptable acid addition salts of the free bases within its scope.
• the compounds of the invention are obtained by reaction of melarsenoxide with an appropriate thiol.
• the reaction can be represented by the equation:
• n and m have the same meaning as above.
• the following compounds are the preferred thiols for use in this invention. They are preferred because they are readily available, known to be non-toxic and because they produce compounds with a high order of activity, a high therapeutic index and low toxicity.
• Pharmaceutically acceptable acid addition salts are those containing non-toxic anions and include, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, lactic, citric, tartaric, succinic, maleic, gluconic and saccharic acids. These acid addition salts are prepared by standard reactions either directly from the initial reaction or from the free base by reaction with the selected acid.
• the general procedure for the preparation of the compounds of this invention is to react melarsenoxide with the selected thiol in an aqueous or lower alkanol medium at a temperature of from 40o to 100°C until all of the reactants have dissolved.
• the reaction products separate as a viscous bottom layer.
• the reaction solvent which may be a mixture of water and a lower alkanol, preferably methanol or ethanol is separated, suitably by decantation.
• the product may be purified by repeated recrystallization together with trituration with a dehydrating solvent, preferably ethanol.
• the preferred recrystallization solvent is water which may contain a small amount of ethanol, e.g. up to 20% by weight.
• thiol i.e. more than two moles of thiol per mole of melarsenoxide. This insures as complete a reaction as possible of the toxic melarsenoxide and limits the amount which may be present as a contaminant in the final product. It is preferred to use at least 10% molar excess of thiol, and for most purposes an excess of from 10 to 20% is acceptable.
• the thiols may be reacted either as free thiols, phosphothionites, or as acid salts such as the hydrochloride or hydrobromide. Accordingly, a product of the invention may be obtained as a free base or an acid addition salt.
• the free cationic melaminylthioarsenites can be prepared according to conventional methods.
• the cationic thioarsenites of the present invention are white powders, soluble in water, dilute acids and alkali, insoluble in acetone, chloroform, and ether. They have no sharp melting point and decompose above
• the products of this invention may be administered alone but will generally be administered with pharmaceutically acceptable, non-toxic carriers, the proportions of which are determined by the suitability and chemical nature of the particular carrier, the chosen route of administration, and standard pharmaceutical practice.
• pharmaceutically acceptable, non-toxic carriers the proportions of which are determined by the suitability and chemical nature of the particular carrier, the chosen route of administration, and standard pharmaceutical practice.
• in combatting various infections or in maintaining therapeutically effective levels in the blood or tissue thay may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar, certain types of clay, etc. They may be enteric coated so as to be more resistant to the acid and digestive enzymes of the stomach.
• intravenous and intramuscular administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution inotonic.
• the compounds of this invention are orders of magnitude more stable than related prior art compounds which have been similarly employed.
• the disodium salt of Compound I the first formula shown above
• the solution becomes slightly cloudy after only 12 hours.
• a precipitate forms in 5 days.
• Compounds X and XIII of this invention in 1% aqueous solution have been held at 37°C for 5 days while still remaining clear. In fact, the solutions remain clear for as long as 3 months at 100°C.
• the compounds of this invention have been screened for useful activity.
• This test system is patterned after the one developed and employed in testing of compounds for activity against Plasmodium berghei maleria in mice.
• the trypanosomiasis system is based on comparisons of responses to test compounds by ICR/HA Swiss mice infected with the Wellcome CT strain of T. rhodesiense as expressed in mean survival times compared with mean survival times of untreated controls.
• Using a standard inoculum it is possible to produce a uniform disease fatal to 100% of untreated animals within 4 to 6 days with a mean survival time of 4.45 ⁇ .25 days.
• Test mice six weeks of age, weighing 30-32 grams receive an intraperitoneal injection of 0.5 ml of a 1:50,000 dilution of heparinized heart blood drawn from donor mice infected 3 days earlier. Compounds are given as a single dose in peanut oil about two hours after parasite inoculation. Five mice per drug level, 20 infected untreated (negative) controls, and 10 infected positive controls are routinely used per test. Positive controls are mice infected and treated at 40 mg/kg with Stilbamidine Isethionate. Routinely compounds are first tested by the subcutaneous route of administration. retested for confirmation at selected drug levels and if the activity is confirmed it is tested by the oral route of administration.
• Example 2 Compound XII 10g III are disolved in a solution of 20.2g VI in 200 ml boiling water. On cooling to 0° of the filtered reaction, mixture XII precipitates, is purified by 3 reprecipitations by cooling of the hot aqueous solution, filtered off, washed with acetone and dried in vacuo. Yield: 7.1g.
• XII is a white hygroscopic powder, soluble in water, EtOH and MeOH, insoluble in acetone, ethylacetate, ether, chloroform. A 1% solution of XII in water remains unchanged for 4 weeks.
• Example 3 Compound XII
• XII 5g III are dissolved, with stirring, in a solution of 5.6g VI in 100 ml boiling MeOH. After cooling to 0°, the reaction mixture is filtered and added to 200 ml ether. The reaction product precipitates as a viscous colorless syrup, which is separated by decantation, washed with 3 portions of 50 ml ether and dried in vacuo. The resulting crusts are soluble in water, EtOH and MeOH, insoluble in ether, chloroform and ethylacetate.
• Example 4 Compound XII 13g III are dissolved with stirring in a solution of 15g VII in 150 ml water warmed to 80°. On cooling of the filtered reaction mixture to 0° , XII forms a viscous transparent bottom layer. The supernatant is decanted, the bottom layer washed with 3 portions of 50 ml ice water. After the last decantation the product is triturated with 200 ml hot EtOH, whereupon it becomes granular. It is filtered off, washed with EtOH and dried over P 2 O 5 in vacuo. Yield 18.6g. XII is a white powder, soluble in water and dilute mineral acids. It is insoluble in EtOH, MeOH, acetone, ether and chloroform. A 1% solution of XII in water remains unchanged at 100 for 4 weeks.
• Example 5 Compound XIII
• Example 6 - Compound XIV 10g III are dissolved with stirring in a solution of 10.1g IX in 100 ml boiling water.
• the filtered solution on standing at 0°, deposits a clear viscous bottom layer which is separated from the supernatant by decantation. On trituration with 100 ml EtOH, the bottom layer becomes solid, granular. It is filtered off and dried in vacuo. The yield is 18g.
• the reaction product is purified by dissolving in the minimal amount of boiling water, followed by cooling and treatment with EtOH as above.
• XIV is a white powder, soluble in water, insoluble in EtOH, MeOH, acetone, chloroform and ether. A 1% solution of XIV in water remains unchanged at 100° for 4 weeks.

Landscapes

• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23447686

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (2)

Citations (3)

Family Cites Families (4)

• 1982
  • 1982-04-12 US US06/367,562 patent/US4514390A/en not_active Expired - Lifetime
• 1983
  • 1983-04-11 WO PCT/US1983/000505 patent/WO1983003606A1/en not_active Ceased
  • 1983-04-11 DE DE8383901552T patent/DE3364051D1/de not_active Expired
  • 1983-04-11 EP EP83901552A patent/EP0105912B1/en not_active Expired
  • 1983-04-11 JP JP58501605A patent/JPS59500519A/ja active Granted
  • 1983-12-08 OA OA58176A patent/OA07604A/xx unknown

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events